[go: up one dir, main page]

ES2032755T3 - Medicamentos conteniendo hexadecil-fosfocolina con efecto antitumoral. - Google Patents

Medicamentos conteniendo hexadecil-fosfocolina con efecto antitumoral.

Info

Publication number
ES2032755T3
ES2032755T3 ES198686906829T ES86906829T ES2032755T3 ES 2032755 T3 ES2032755 T3 ES 2032755T3 ES 198686906829 T ES198686906829 T ES 198686906829T ES 86906829 T ES86906829 T ES 86906829T ES 2032755 T3 ES2032755 T3 ES 2032755T3
Authority
ES
Spain
Prior art keywords
hexadecil
phosphocoline
medicines containing
eventually
antitumoral effect
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES198686906829T
Other languages
English (en)
Inventor
Hansjorg Eibl
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Max Planck Gesellschaft zur Foerderung der Wissenschaften
Original Assignee
Max Planck Gesellschaft zur Foerderung der Wissenschaften
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Max Planck Gesellschaft zur Foerderung der Wissenschaften filed Critical Max Planck Gesellschaft zur Foerderung der Wissenschaften
Application granted granted Critical
Publication of ES2032755T3 publication Critical patent/ES2032755T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
    • A61K31/685—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/075—Ethers or acetals
    • A61K31/08—Ethers or acetals acyclic, e.g. paraformaldehyde
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/06—Phosphorus compounds without P—C bonds
    • C07F9/22—Amides of acids of phosphorus
    • C07F9/24—Esteramides
    • C07F9/2454—Esteramides the amide moiety containing a substituent or a structure which is considered as characteristic
    • C07F9/2458—Esteramides the amide moiety containing a substituent or a structure which is considered as characteristic of aliphatic amines

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Respiratory Apparatuses And Protective Means (AREA)
  • Adhesives Or Adhesive Processes (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Steroid Compounds (AREA)
  • Electrically Operated Instructional Devices (AREA)
  • Ultra Sonic Daignosis Equipment (AREA)
  • Measurement And Recording Of Electrical Phenomena And Electrical Characteristics Of The Living Body (AREA)

Abstract

Procedimiento para la preparación de un medicamento (activo antitumoralmente), caracterizado porque se mezcla u homogeneiza hexadecilfosfocolina con usuales materiales de vehículo y/o materiales diluyentes o auxiliares fisiológicamente compatibles, a temperaturas comprendidas entre 20 y 120º C, y eventualmente la mezcla así obtenida, para la producción de preparados que en una unidad de dosificación contienen dentro de celdillas huecas de tamaño apropiado o bien se envasa en cápsulas de tamaño apropiado o se granula, y luego se prensa, eventualmente con adición de otros materiales auxiliares usuales, a la forma de tabletas.
ES198686906829T 1985-12-04 1986-12-04 Medicamentos conteniendo hexadecil-fosfocolina con efecto antitumoral. Expired - Lifetime ES2032755T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE3542893 1985-12-04
DE3606631 1986-02-28

Publications (1)

Publication Number Publication Date
ES2032755T3 true ES2032755T3 (es) 1993-03-01

Family

ID=25838509

Family Applications (2)

Application Number Title Priority Date Filing Date
ES198686906829T Expired - Lifetime ES2032755T3 (es) 1985-12-04 1986-12-04 Medicamentos conteniendo hexadecil-fosfocolina con efecto antitumoral.
ES198787900101T Expired - Lifetime ES2038215T3 (es) 1985-12-04 1986-12-04 Medicamentos.

Family Applications After (1)

Application Number Title Priority Date Filing Date
ES198787900101T Expired - Lifetime ES2038215T3 (es) 1985-12-04 1986-12-04 Medicamentos.

Country Status (15)

Country Link
US (2) US4837023A (es)
EP (4) EP0225608A3 (es)
JP (2) JPH0637393B2 (es)
AT (2) ATE75608T1 (es)
CA (2) CA1338627C (es)
DE (4) DE3641491A1 (es)
DK (2) DK172954B1 (es)
ES (2) ES2032755T3 (es)
FI (2) FI873363A0 (es)
GR (2) GR3002487T3 (es)
HU (2) HU203201B (es)
IE (2) IE59778B1 (es)
NO (2) NO175620C (es)
PT (2) PT83872B (es)
WO (2) WO1987003480A2 (es)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5916884A (en) * 1985-12-04 1999-06-29 Max-Planck-Gesellschaft Zur Foederung Der Wissenschaften Compositions containing a mixture of phosphorus compounds and alkylglycerols
CA2001401A1 (en) * 1988-10-25 1990-04-25 Claude Piantadosi Quaternary amine containing ether or ester lipid derivatives and therapeutic compositions
US5182271A (en) * 1989-08-10 1993-01-26 Sandoz Ltd. Thioether, keto-ester and alkyl phospholipids useful in treating multiple sclerosis
ES2086395T3 (es) * 1989-08-10 1996-07-01 Sandoz Ltd Fosfolipidos para el tratamiento de esclerosis multiple.
US5290769A (en) * 1989-09-27 1994-03-01 Asta Pharma Aktiengesellschaft Use of hexadecylphosphocholine for the treatment of psoriasis
EP0916343A1 (de) * 1989-09-27 1999-05-19 ASTA Medica Aktiengesellschaft Verwendung von Alkylphosphorsäure-Verbindungen zur Bekämpfung von Psoriasis-Erkrankungen
DE4111105A1 (de) * 1991-04-05 1992-10-08 Max Planck Gesellschaft Neue erucyl-, brassidyl- und nervonylderivate
US5506217A (en) * 1991-04-25 1996-04-09 The University Of British Columbia Phosphonates as anti-cancer agents
US5369097A (en) * 1991-04-25 1994-11-29 The University Of British Columbia Phosphonates as anti-cancer agents
ES2108715T3 (es) * 1991-07-04 1998-01-01 Asta Medica Ag Procedimiento para la preparacion de alquilfosfocolinas y purificacion de las mismas.
US6254879B1 (en) 1991-09-27 2001-07-03 Max-Planck-Gessellschaft zun Förderung der Wissenschaften e.V. Methods of treating protozoal diseases
US5298655A (en) * 1991-09-27 1994-03-29 Merck & Co., Inc. Farnesyl pyrophosphate analogs
DE4132344A1 (de) * 1991-09-27 1993-04-01 Max Planck Gesellschaft Verfahren zur herstellung eines arzneimittels zur oralen oder topischen verabreichung bei der behandlung von leishmaniasis
US6172050B1 (en) 1992-07-11 2001-01-09 Asta Medica Aktiengesellschaft Phospholipid derivatives
DE4222910A1 (de) * 1992-07-11 1994-01-13 Asta Medica Ag Neue Phospholipidderivate
DE4235911A1 (de) * 1992-10-23 1994-04-28 Asta Medica Ag Stabilisierte Hexadecylphosphocholinlösungen in Glycerinalkylethern
DE69431596T4 (de) * 1993-06-10 2003-10-30 University Of North Carolina At Chapel Hill, Chapel Hill (phospho)lipide zum bekämpfen einer hepatitis b-infektion
CA2171281C (en) 1993-09-09 1998-12-29 Romeo Rang Immunomodulating compositions from bile
US6551623B1 (en) 1993-09-09 2003-04-22 Lorus Therapeutics Inc. Immunomodulating compositions from bile
US7135584B2 (en) * 1995-08-07 2006-11-14 Wake Forest University Lipid analogs for treating viral infections
EP1852121A3 (en) * 1994-08-29 2007-11-21 Wake Forest University Lipid analogs for treating viral infections
US5574025A (en) * 1994-10-26 1996-11-12 Merck & Co., Inc. Inhibitors of prenyl-protein transferases
WO1996024598A1 (en) * 1995-02-10 1996-08-15 The University Of British Columbia [4-hexadecyl-3-methoxy-butyl] phosphonic acid and its protein conjugates useful as anti-cancer agents
BR9607967A (pt) 1995-03-16 1998-01-13 Imutec Pharma Inc Uso de composições imunomodulares extraídas da bile para o tratamento das desordens do sistema imunológico fabricação do medicamento e emprego do mesmo
KR100499190B1 (ko) * 1996-03-29 2006-04-17 교와 핫꼬 고교 가부시끼가이샤 육모제
US20040101569A1 (en) * 1996-05-16 2004-05-27 Lorus Therapeutics Inc. Immunomodulating compositions from bile
US6121245A (en) * 1997-01-29 2000-09-19 Firshein; Richard N. Method of treating cancer using alkylglycerols in conjunction with chemotherapy
SE9701912D0 (sv) * 1997-05-22 1997-05-22 Interhealth Ab Pharmaceutical composition and use thereof
US7582678B2 (en) * 1997-07-09 2009-09-01 D-Pharm Limited Use of branched-chain fatty acids and derivatives thereof for the treatment of pain
EP1051159B1 (en) * 1998-01-22 2002-04-10 Zentaris AG Solid pharmaceutical compositions containing miltefosine for oral administration in the treatment of leishmaniasis
US7026469B2 (en) * 2000-10-19 2006-04-11 Wake Forest University School Of Medicine Compositions and methods of double-targeting virus infections and cancer cells
IL137672A0 (en) 2000-08-03 2001-10-31 Dpharm Ltd Derivatives of branched-chain lipophilic molecules and uses thereof
US7309696B2 (en) 2000-10-19 2007-12-18 Wake Forest University Compositions and methods for targeting cancer cells
CN1486289A (zh) * 2001-05-29 2004-03-31 皇家菲利浦电子有限公司 金属-陶瓷的结合
CN100469131C (zh) * 2001-08-31 2009-03-11 汤姆森许可公司 实现条件存取系统和传输、接收及处理内容的方法和设备
BR0215680A (pt) * 2002-04-26 2005-02-01 Rudolf Perl Composição farmacêutica oral estável
US20050187191A1 (en) * 2004-02-20 2005-08-25 Kucera Louis S. Methods and compositions for the treatment of respiratory syncytial virus
AU2006328479B2 (en) 2005-12-19 2012-03-08 Aeterna Zentaris Gmbh Alkyl phospholipid derivatives with reduced cytotoxicity and uses thereof
ES2391226T3 (es) * 2006-12-20 2012-11-22 Alphaptose Gmbh Forma farmacéutica tópica que comprende compuestos de glicerol tri-sustituido
JP2011057647A (ja) * 2009-09-14 2011-03-24 Adeka Corp 化粧料
EP2723347B1 (en) 2011-06-24 2019-09-04 GRI Bio, Inc. Prevention and treatment of inflammatory conditions
CN102491994B (zh) * 2011-12-07 2014-10-15 宁波九胜创新医药科技有限公司 一种胆碱磷酸烷基酯的制备方法
BR112017012134A2 (pt) * 2014-12-09 2018-01-23 Gri Bio, Inc. prevenção e tratamento de condições inflamatórias

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3225227A1 (de) * 1982-07-06 1984-01-12 Max Planck Gesellschaft zur Förderung der Wissenschaften e.V., 3400 Göttingen Derivate des n.n-bis-(2-chlor-aethyl)-phosphorsaeureamids
JPS5984824A (ja) * 1982-11-08 1984-05-16 Takeda Chem Ind Ltd 抗腫瘍剤
US4690935A (en) * 1983-03-31 1987-09-01 Wayne State University Inhibition of tumor growth and metastasis with calcium channel blocker compounds
JPS60184092A (ja) 1984-03-01 1985-09-19 Kao Corp リン酸エステルおよびその製法

Also Published As

Publication number Publication date
DK393187A (da) 1987-07-28
ES2038215T3 (es) 1993-07-16
EP0230575A3 (de) 1987-12-02
NO873244L (no) 1987-10-01
NO175620B (es) 1994-08-01
IE59778B1 (en) 1994-04-06
JP2857084B2 (ja) 1999-02-10
IE59777B1 (en) 1994-04-06
WO1987003480A3 (en) 1988-02-25
NO174877B (no) 1994-04-18
PT83873A (de) 1987-01-01
DK393187D0 (da) 1987-07-28
WO1987003478A3 (en) 1987-09-24
ATE64529T1 (de) 1991-07-15
ATE75608T1 (de) 1992-05-15
FI873363A7 (fi) 1987-08-03
DK172954B1 (da) 1999-10-18
PT83872B (pt) 1989-01-17
JPS63501719A (ja) 1988-07-14
DE3641379A1 (de) 1987-09-03
CA1280369C (en) 1991-02-19
HU208143B (en) 1993-08-30
EP0230575A2 (de) 1987-08-05
NO174877C (no) 1994-07-27
HUT44431A (en) 1988-03-28
WO1987003480A2 (en) 1987-06-18
DE3679908D1 (de) 1991-07-25
FI873364A0 (fi) 1987-08-03
WO1987003478A2 (en) 1987-06-18
DE19375061I2 (de) 2008-11-20
IE863177L (en) 1987-06-04
FI873363L (fi) 1987-08-03
CA1338627C (en) 1996-10-01
EP0225608A2 (de) 1987-06-16
FI873364A7 (fi) 1987-08-03
NO873243D0 (no) 1987-08-03
EP0248047A1 (de) 1987-12-09
EP0248062A1 (de) 1987-12-09
HU203201B (en) 1991-06-28
IE863176L (en) 1987-06-04
DK398587A (da) 1987-07-30
JPH0637393B2 (ja) 1994-05-18
FI873363A0 (fi) 1987-08-03
NO873243L (no) 1987-10-02
EP0225608A3 (de) 1987-10-28
PT83873B (pt) 1989-01-17
NO175620C (no) 1994-11-09
GR3002487T3 (en) 1992-12-30
NO873244D0 (no) 1987-08-03
PT83872A (de) 1987-01-01
GR3005168T3 (es) 1993-05-24
JPH0859677A (ja) 1996-03-05
US4837023A (en) 1989-06-06
HUT44441A (en) 1988-03-28
DE3641491A1 (de) 1987-09-17
EP0248062B1 (de) 1992-05-06
DK398587D0 (da) 1987-07-30
EP0248047B1 (de) 1991-06-19
US5049552A (en) 1991-09-17

Similar Documents

Publication Publication Date Title
ES2032755T3 (es) Medicamentos conteniendo hexadecil-fosfocolina con efecto antitumoral.
AU579355B2 (en) Storage-stable, quick disintegrating pressed shapes containing pharmaceutical active substances
FI840851A0 (fi) Foerfarande foer framstaellning av farmakologiskt aktiva omeprazolsalter
ES2060737T3 (es) Procedimiento de preparacion de un granulado farmaceutico.
IL96699A0 (en) Formulations containing l-carnitine
PT86186A (en) Process for the preparation of benzimidazol derivatives and of pharmaceutical compositions containing the same
EP0137542A3 (en) Pharmaceutical composition for the treatment of states of acute renal insufficiency
ES2043117T3 (es) Composicon que contiene fosfolipidos, un proceso para su preparacion, y su uso como excipiente para substancias farmaceuticas.
ES2067250T3 (es) Preparado farmaceutico sin disolventes para administracion oral, con liberacion retardada de la sustancia activa y procedimiento para su fabricacion.
DK154537C (da) Hurtig-disintegrerende komprimerede laegemiddelpraeparater
IL53596A (en) Biological cells externally modified for controlled release,in the spleen and/or liver,of pharmaceutically active substances comprised therein,their preparation and pharmaceutical compositions containing them
NZ225242A (en) Pad printing process for manufacturing a pharmaceutical presentation and/or dosage form for active ingredients of drugs
NZ225066A (en) Solid drug preparations containing 2-phenyl-1,2-benzisoselenazol-3(2h)-one (ebselen)
MY102728A (en) Improvemant in and relating to effervescent acetlysalicylic acid tablets
DE3272602D1 (en) Solid galenic form for oral administration and process for its preparation
JPS6429314A (en) Medicine dosage
ZA872868B (en) The liquidization of pharmaceutical preparations for filling soft gelatine capsules therewith
ES2046270T3 (es) Un procedimiento para fabricar una composicion farmaceutica en forma de una tableta de compresion multiple.
ES2059312T3 (es) Medicamento que puede administrarse por via nasal, procedimiento para su preparacion y su aplicacion.
PT81429B (pt) Processo para a preparacao de formulacoes ou suspensoes estaveis de medicamentos solidos, contendo 4-hidroxi- ou 4-aciloxi-4-androsteno-3,17-dionas
MY101916A (en) Etoposide oral dosage form.
ES8601687A1 (es) Procedimiento para producir una tableta de administracion oral de liberacion controlada, independiente del ph
ATE15329T1 (de) Pharmazeutische grundmasse und praeparate.
PT86061A (en) Process for the preparation of analgesic pharmaceutical compositions containing a synergic mixture of ibuprofen with tizanidine
GB942873A (en) Pharmaceutical compositions containing resin-drug adsorbates

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 248047

Country of ref document: ES

SPCF Request for supplementary protection certificate filed

Free format text: MILTEFOSINA (MILTEX)

Spc suppl protection certif: C9900046

Filing date: 19991227

SPCG Supplementary protection certificate granted

Free format text: MILTEFOSINA (MILTEX)

Spc suppl protection certif: C9900046

Filing date: 19991227

Expiry date: 20071012

Effective date: 20030901